Tyrosine Phosphorylation of the Nuclear Receptor Coactivator AIB1/SRC-3 Is Enhanced by Abl Kinase and Is Required for Its Activity in Cancer Cells

ABSTRACT Overexpression and activation of the steroid receptor coactivator amplified in breast cancer 1 (AIB1)/steroid receptor coactivator-3 (SRC-3) have been shown to have a critical role in oncogenesis and are required for both steroid and growth factor signaling in epithelial tumors. Here, we report a new mechanism for activation of SRC coactivators. We demonstrate regulated tyrosine phosphorylation of AIB1/SRC-3 at a C-terminal tyrosine residue (Y1357) that is phosphorylated after insulin-like growth factor 1, epidermal growth factor, or estrogen treatment of breast cancer cells. Phosphorylated Y1357 is increased in HER2/neu (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2) mammary tumor epithelia and is required to modulate AIB1/SRC-3 coactivation of estrogen receptor alpha (ERα), progesterone receptor B, NF-κB, and AP-1-dependent promoters. c-Abl (v-Abl Abelson murine leukemia viral oncogene homolog 1) tyrosine kinase directly phosphorylates AIB1/SRC-3 at Y1357 and modulates the association of AIB1 with c-Abl, ERα, the transcriptional cofactor p300, and the methyltransferase coactivator-associated arginine methyltransferase 1, CARM1. AIB1/SRC-3-dependent transcription and phenotypic changes, such as cell growth and focus formation, can be reversed by an Abl kinase inhibitor, imatinib. Thus, the phosphorylation state of Y1357 can function as a molecular on/off switch and facilitates the cross talk between hormone, growth factor, and intracellular kinase signaling pathways in cancer.

[1]  A. Boureux,et al.  The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells , 2007, Oncogene.

[2]  B. O’Malley,et al.  Signaling within a Coactivator Complex: Methylation of SRC-3/AIB1 Is a MolecularSwitch for Complex Disassembly , 2006, Molecular and Cellular Biology.

[3]  J. Torchia,et al.  Microtubule-Dependent Subcellular Redistribution of the Transcriptional Coactivator p/CIP , 2002, Molecular and Cellular Biology.

[4]  A. Pendergast The Abl family kinases: mechanisms of regulation and signaling. , 2002, Advances in cancer research.

[5]  Jing Liang,et al.  Coordinated Regulation of AIB1 Transcriptional Activity by Sumoylation and Phosphorylation* , 2006, Journal of Biological Chemistry.

[6]  N. Koibuchi,et al.  TRAM-1, A Novel 160-kDa Thyroid Hormone Receptor Activator Molecule, Exhibits Distinct Properties from Steroid Receptor Coactivator-1* , 1997, The Journal of Biological Chemistry.

[7]  E. Gehan,et al.  The Nuclear Receptor Coactivator AIB1 Mediates Insulin-like Growth Factor I-induced Phenotypic Changes in Human Breast Cancer Cells , 2004, Cancer Research.

[8]  I. Raška,et al.  P38MAPK‐dependent phosphorylation and degradation of SRC‐3/AIB1 and RARα‐mediated transcription , 2006, The EMBO journal.

[9]  D. Srinivasan,et al.  Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival , 2008, Oncogene.

[10]  M. Sternberg,et al.  Enhanced genome annotation using structural profiles in the program 3D-PSSM. , 2000, Journal of molecular biology.

[11]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[12]  A. Wellstein,et al.  An Isoform of the Coactivator AIB1 That Increases Hormone and Growth Factor Sensitivity Is Overexpressed in Breast Cancer* , 2001, The Journal of Biological Chemistry.

[13]  B. O’Malley,et al.  SRC-3 Coactivator Functional Lifetime Is Regulated by a Phospho-Dependent Ubiquitin Time Clock , 2007, Cell.

[14]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[15]  A. Wellstein,et al.  Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. , 2007, Cancer research.

[16]  Baljit Singh,et al.  Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue , 2001, Breast Cancer Research and Treatment.

[17]  Giulio Superti‐Furga,et al.  c‐Abl is an effector of Src for growth factor‐induced c‐myc expression and DNA synthesis , 2002, The EMBO journal.

[18]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[19]  Jijie Gu,et al.  p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage , 1999, Nature.

[20]  Y. Zeng,et al.  Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. , 2005, Human pathology.

[21]  Anton Wellstein,et al.  E6AP mediates regulated proteasomal degradation of the nuclear receptor coactivator amplified in breast cancer 1 in immortalized cells. , 2006, Cancer research.

[22]  M. Ittmann,et al.  Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. , 2006, Cancer research.

[23]  A. Kazlauskas,et al.  c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. , 1999, Genes & development.

[24]  B. O’Malley,et al.  Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis. , 2005, Cancer research.

[25]  M. Louie,et al.  ACTR/AIB1 Functions as an E2F1 Coactivator To Promote Breast Cancer Cell Proliferation and Antiestrogen Resistance , 2004, Molecular and Cellular Biology.

[26]  B. O’Malley,et al.  Specific Amino Acid Residues in the Basic Helix-Loop-Helix Domain of SRC-3 Are Essential for Its Nuclear Localization and Proteasome-Dependent Turnover , 2006, Molecular and Cellular Biology.

[27]  G. Superti-Furga,et al.  A nuclear tyrosine phosphorylation circuit: c‐Jun as an activator and substrate of c‐Abl and JNK , 2000, The EMBO journal.

[28]  M. Tilli,et al.  Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice. , 2005, Molecular endocrinology.

[29]  R. V. van Etten,et al.  Cycling, stressed-out and nervous: cellular functions of c-Abl. , 1999, Trends in cell biology.

[30]  C. Powers,et al.  Ribozyme Targeting Demonstrates That the Nuclear Receptor Coactivator AIB1 Is a Rate-limiting Factor for Estrogen-dependent Growth of Human MCF-7 Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[31]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[32]  A. Mandarino,et al.  Role of c-Abl in Directing Metabolic versus Mitogenic Effects in Insulin Receptor Signaling* , 2007, Journal of Biological Chemistry.

[33]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[34]  W. Sellers,et al.  High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. , 2004, Cancer cell.

[35]  Oliver Hantschel,et al.  Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. , 2006, Molecular cell.

[36]  Yusuke Nakamura,et al.  Amplification and over‐expression of the AIB1 nuclear receptor co‐activator gene in primary gastric cancers , 2000, International journal of cancer.

[37]  N. Heisterkamp,et al.  Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site , 1997, Oncogene.

[38]  O. Hermanson,et al.  Regulation of somatic growth by the p160 coactivator p/CIP. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Hui Li,et al.  RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Southey,et al.  Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. , 2001, Cancer research.

[41]  A. Wellstein,et al.  Induction of the Angiogenic Modulator Fibroblast Growth Factor-binding Protein by Epidermal Growth Factor Is Mediated through Both MEK/ERK and p38 Signal Transduction Pathways* , 2000, The Journal of Biological Chemistry.

[42]  James D. Griffin,et al.  p130CAS Forms a Signaling Complex with the Adapter Protein CRKL in Hematopoietic Cells Transformed by the BCR/ABL Oncogene* , 1996, The Journal of Biological Chemistry.

[43]  A. Maitra,et al.  Overexpression of the Nuclear Receptor Coactivator AIB1 (SRC-3) during Progression of Pancreatic Adenocarcinoma , 2004, Clinical Cancer Research.

[44]  G. Superti-Furga,et al.  A Myristoyl/Phosphotyrosine Switch Regulates c-Abl , 2003, Cell.

[45]  Adrian V. Lee,et al.  AIB1/SRC-3 Deficiency Affects Insulin-Like Growth Factor I Signaling Pathway and Suppresses v-Ha-ras-induced Breast Cancer Initiation and Progression in Mice , 2004, Cancer Research.

[46]  S. Feller,et al.  c‐Abl kinase regulates the protein binding activity of c‐Crk. , 1994, The EMBO journal.

[47]  J. Auwerx,et al.  Absence of the steroid receptor coactivator‐3 induces B‐cell lymphoma , 2006, The EMBO journal.

[48]  Adam T. Szafran,et al.  Regulation of SRC-3 Intercompartmental Dynamics by Estrogen Receptor and Phosphorylation , 2007, Molecular and Cellular Biology.

[49]  T. Hunter,et al.  Critical roles of the p160 transcriptional coactivators p/CIP and SRC-1 in energy balance. , 2006, Cell metabolism.

[50]  D. Baltimore,et al.  Identification of the Abl- and rasGAP-Associated 62 kDa Protein as a Docking Protein, Dok , 1997, Cell.

[51]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[52]  M. Tsai,et al.  Role of the Steroid Receptor Coactivator SRC-3 in Cell Growth , 2003, Molecular and Cellular Biology.

[53]  C. Cordon-Cardo,et al.  Autocrine PDGFR signaling promotes mammary cancer metastasis. , 2006, The Journal of clinical investigation.

[54]  J. Qin,et al.  Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. , 2004, Molecular cell.

[55]  C. Deng,et al.  The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Torchia,et al.  The Activity and Stability of the Transcriptional Coactivator p/CIP/SRC-3 Are Regulated by CARM1-Dependent Methylation , 2006, Molecular and Cellular Biology.

[58]  A. Zhang,et al.  Nuclear localization of coactivator RAC3 is mediated by a bipartite NLS and importin alpha3. , 2006, Biochemical and biophysical research communications.

[59]  N. Heisterkamp,et al.  Crkl Is Complexed with Tyrosine-phosphorylated Cbl in Ph-positive Leukemia (*) , 1995, The Journal of Biological Chemistry.

[60]  R. V. van Etten,et al.  c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory Tyrosines* , 2000, The Journal of Biological Chemistry.

[61]  J. Auwerx,et al.  Oncogenic steroid receptor coactivator-3 is a key regulator of the white adipogenic program , 2006, Proceedings of the National Academy of Sciences.

[62]  Charis Eng,et al.  Catalytic specificity of protein-tyrosine kinases is critical for selective signalling , 1995, Nature.

[63]  Michael B. Yaffe,et al.  Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs , 2003, Nucleic Acids Res..